Genetic Association Between CDKN1B rs2066827 Polymorphism and Susceptibility to Cancer
- PMID: 26579796
- PMCID: PMC4652805
- DOI: 10.1097/MD.0000000000001217
Genetic Association Between CDKN1B rs2066827 Polymorphism and Susceptibility to Cancer
Abstract
Much attention has been directed to the association between cancer risk and rs2066827 polymorphism of the CDKN1B gene. However, the results are indefinitive and inconclusive. This study was devised to evaluate the hypothesis that rs2066827 polymorphism is associated with the risk of cancer.Computer-based databases (EMBASE, PubMed, and CNKI) were used to seek all case-control studies evaluating rs2066827 polymorphism and susceptibility to cancer. The genetic risk was assessed by calculating pooled odds ratio (OR) with its corresponding 95% confidence interval (CI). Fixed-effects pooled ORs were calculated by the Mantel-Haenszel method (Ph > 0.05), and random-effects pooled ORs were estimated by the DerSimonian-Laird method (Ph < 0.05).Data on rs2066827 polymorphism and cancer risk were available for 9038 cancer cases and 11,596 controls participating in 17 studies. Carriage of a TG genotype was associated with a minor but significant decrease in the risk of cancer (pooled OR 0.92, 95% CI: 0.86-0.99; model, TG vs. TT). We observed a moderately decreased risk of ovarian cancer based on 1829 cases and 2868 controls (pooled OR 0.85, 95% CI: 0.74-0.97; model, TG vs. TT). A slightly deceased risk of cancer was also indicated in Caucasians consisting of 6707 cases and 8279 controls (pooled OR 0.91, 95% CI: 0.85-0.98; model, TG vs. TT).These data suggest that carriage of a TG genotype at rs2066827 polymorphism may be associated with decreased susceptibility to cancer, ovarian cancer in particular.
Conflict of interest statement
The authors have no conflicts of interest to disclose.
Figures




Similar articles
-
Association of CDKN1B gene polymorphisms with susceptibility to breast cancer: a meta-analysis.Mol Biol Rep. 2013 Nov;40(11):6371-7. doi: 10.1007/s11033-013-2751-8. Mol Biol Rep. 2013. PMID: 24078094
-
Lack of association between cyclin-dependent kinase inhibitor 1B rs2066827 polymorphism and breast cancer susceptibility.Tumour Biol. 2014 Jun;35(6):5527-31. doi: 10.1007/s13277-014-1727-1. Epub 2014 Feb 13. Tumour Biol. 2014. PMID: 24523023
-
Genetic association between the cyclin-dependent kinase inhibitor gene p27/Kip1 polymorphism (rs34330) and cancer susceptibility: a meta-analysis.Sci Rep. 2017 Mar 20;7:44871. doi: 10.1038/srep44871. Sci Rep. 2017. PMID: 28317869 Free PMC article.
-
The TERT rs2736100 polymorphism and cancer risk: a meta-analysis based on 25 case-control studies.BMC Cancer. 2012 Jan 5;12:7. doi: 10.1186/1471-2407-12-7. BMC Cancer. 2012. PMID: 22221621 Free PMC article. Review.
-
Mitogen-Activated Protein Kinase Kinase 4 Gene Polymorphism and Cancer Risk.Medicine (Baltimore). 2015 Nov;94(44):e0938. doi: 10.1097/MD.0000000000000938. Medicine (Baltimore). 2015. PMID: 26554761 Free PMC article. Review.
Cited by
-
Germline CDKN1B Loss-of-Function Variants Cause Pediatric Cushing's Disease With or Without an MEN4 Phenotype.J Clin Endocrinol Metab. 2020 Jun 1;105(6):1983-2005. doi: 10.1210/clinem/dgaa160. J Clin Endocrinol Metab. 2020. PMID: 32232325 Free PMC article.
-
Genome-wide DNA copy number analysis in clonally expanded human ovarian cancer cells with distinct invasive/migratory capacities.Oncotarget. 2017 Feb 28;8(9):15136-15148. doi: 10.18632/oncotarget.14767. Oncotarget. 2017. PMID: 28122348 Free PMC article.
-
p27-V109G Polymorphism Is Not Associated with the Risk of Prostate Cancer: A Case-Control Study of Han Chinese Men in Central China.Dis Markers. 2018 Mar 20;2018:1418609. doi: 10.1155/2018/1418609. eCollection 2018. Dis Markers. 2018. PMID: 29750086 Free PMC article.
-
MEN4 and CDKN1B mutations: the latest of the MEN syndromes.Endocr Relat Cancer. 2017 Oct;24(10):T195-T208. doi: 10.1530/ERC-17-0243. Epub 2017 Aug 19. Endocr Relat Cancer. 2017. PMID: 28824003 Free PMC article. Review.
References
-
- Morgan DO. Principles of CDK regulation. Nature 1995; 374:131–134. - PubMed
-
- Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999; 13:1501–1512. - PubMed
-
- Sherr CJ. Cancer cell cycles. Science 1996; 274:1672–1677. - PubMed
-
- Wingate H, Bedrosian I, Akli S, et al. The low molecular weight (LMW) isoforms of cyclin E deregulate the cell cycle of mammary epithelial cells. Cell Cycle 2003; 2:461–466. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous